Jade Biosciences Prices Public Offering
Analysis based on 16 articles · First reported Jun 03, 2026 · Last updated Jun 04, 2026
The public offering by Altor BioScience is expected to raise $150.0 million, providing significant capital for its clinical trials and research, which could positively impact its stock price and future growth prospects. The involvement of major investment banks like Jefferies, Toronto-Dominion Bank — TD Cowen, and UBS in managing the offering indicates market confidence and facilitates the capital raise.
Altor BioScience, a clinical-stage biotechnology company, announced the pricing of a public offering of 10,000,000 shares of its common stock at $15.00 per share, aiming to raise $150.0 million. The offering is expected to close on June 5, 2026. Altor BioScience has also granted the underwriters a 30-day option to purchase an additional 1,500,000 shares. The net proceeds from this offering will be used by Altor BioScience to fund clinical trials, preclinical studies, manufacturing, and other general corporate purposes. Jefferies, Toronto-Dominion Bank — TD Cowen, and UBS are acting as joint book-running managers, with LifeSci Capital as a passive book-running manager and BTIG as a lead manager. The securities are being offered pursuant to a shelf registration statement filed with the United States — United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard